Our product range comprises several specialised lock solutions to meet the individual needs of every patient. With 500 IU/ml of heparin, TauroLock™-HEP500 is designed to minimise occlusion rates throughout dialysis treatment.
Indication and effect
TauroLock™-HEP500 can be used with devices for venous vascular access. We recommend using it with catheters for haemodialysis. This lock solution prevents the formation of bacterial biofilm: Patients remain protected against catheter-related infections and maintain a high patency rate.
TauroLock™-Hep500 consists of three active ingredients:
- heparin (500 units per ml)
- citrate (4 %)
Taurolidine has a broad antimicrobial activity (incl. MRSA and VRE) against gram-positive and gram-negative bacteria and fungi (e.g. Candida). Heparin and citrate both prevent occlusions within the catheter.
In-between treatment sessions, TauroLock™-HEP500 is instilled into the vascular access system. Please note that medical staff have to check the filling volume of the respective catheter or port system.
Taurolidine-based lock solutions such as TauroLock™-HEP500 are recommended in national and international guidelines. For patients suffering from heparin-induced thrombocytopenia (HIT), we offer two heparin-free alternatives:
TauroLock™-HEP500 should not be used for vascular access systems (VAD) if the patient:
- has been diagnosed with HIT,
- has displayed a hypersensitive reaction to citrate or taurolidine,
- is taking medication which interferes with either citrate, heparin, or taurolidine.
Alternatively, you can rely on TauroLock™ and/or TauroLock™-U25.000 to prevent catheter-related complications.
TauroLock™-HEP500 must be aspirated before the next treatment.
TauroLock™-HEP500 is available in two sizes:
- ampoules of 5 ml (single dose, 10 ampoules per box)
- vials of 10 ml (mulitple dose, 100 vials per box)
Storage & transport
TauroLock™-HEP500 must be stored at temperatures between 15 °C and 30 °C. While ampoules are designed for single use, vials remain usable within a period of 48 hours. Please note that you must not freeze TauroLock™-HEP500 under any circumstances.
More about TauroLock™-HEP500
National guideline recommendations, e.g. DGfN 2019:
“Between dialysis treatments, the central venous access device may be blocked using a diluted heparin solution. Heparin, however, does not have any antibacterial properties. Therefore, … taurolidine-citrate solutions may be considered.“
Between dialysis treatments, the central venous access device may be blocked using a diluted heparin solution. Heparin, however, does not have any antibacterial properties. Antibacterial lock solutions should be preferred since they reduce the rate of catheter-related bacteraemias considerably. The use of antibiotics cannot be recommended due to the potential development of resistance. Alternatively, citrate in various concentrations (4 %, 30 % or 46 %) as well as taurolidine-citrate solutions may be considered. Due to the risk of severe cardiac arrhythmias, highly concentrated citrate must be strictly administered by trained staff according to the instructions of the manufacturer. Citrate at 4 % has proven effective against low potential of complications and are broadly accepted standard amongst citrate lock solution at present.
“…The bacteremia rates from all causes were 1.33, 1.22 and 3.25 per 1000 catheter- days (p < 0.001) in the TCH*, TC** and heparin groups respectively. Addition of 500 U⁄ml heparin to TC reduces the need for thrombolysis without increasing bacteremia and may achieve patency comparable to heparin 5000 U⁄ ml…”
For personal inquiries, feel free to contact us via phone or email.
Our international distributors based in more than 50 countries will answer your requests ASAP.